On March 29, the Collaborative Innovation Conference of the National Key Laboratory of Neurology and Tumor Drug Research and Development was held in Nanjing on March 29, which released the Pioneer’s “Seeking Plan”. A scientific steering committee composed of 11 academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering made directional planning for the project and supported disruptive innovation in the field of neurology and tumor drug research and development from 0 to 1. The Qiusuo Plan will continue to invest a total of 2 billion yuan over 5 years, mainly targeting ten research directions, namely the treatment methods that fundamentally reverse the high mortality and disability rates of stroke; Discovery, validation, and drug development of potential targets for precise treatment of neurodegenerative diseases; Discovery, validation, and drug development validation of targets (or combinations) that are expected to significantly improve the current efficacy of cancer treatment; Clinical applications of new generation gene editing and related technologies; The therapeutic application of RNA interference mRNA technology in neurodegenerative diseases, tumors, and infections; Clinical application of next-generation cell therapy; Clinical application of new generation delivery technology; Clinical application of anti-aging related mechanisms; Application of clinical data and AI technology in target discovery and validation; AI technology is applied to predict the clinical efficacy and safety of drug development. (Every time)
Scan code to share